News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
111 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17894)
Month
January (4450)
February (4428)
March (5683)
April (4545)
May (5703)
June (4805)
July (3912)
August (4762)
September (4260)
October (3860)
November (4837)
December (2683)
Day
1 (221)
2 (198)
3 (246)
4 (134)
5 (2)
6 (26)
7 (189)
8 (263)
9 (229)
10 (265)
11 (138)
12 (2)
13 (5)
14 (238)
15 (260)
16 (218)
17 (239)
18 (111)
19 (1)
20 (3)
21 (103)
22 (312)
23 (250)
24 (321)
25 (115)
26 (6)
27 (5)
28 (328)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
The Global Contraceptives Market To Garner A Value Of US$ 37,242.7 Mn By 2025-End
Fact.MR – A Market research and competitive intelligence provider: The global contraceptives market shall surpass a market valuation of US$ 37,242.7 Mn by the end of 2025.
February 18, 2022
·
5 min read
Business
Karen L. Ling joins Galderma’s Advisory Committee
Galderma, the world’s largest independent dermatology company, announced that Karen L. Ling will join its Advisory Committee, effective March 1, 2022.
February 18, 2022
·
2 min read
Dermatology Excimer Lasers Market – New Development and Demand Growing Opportunities
Dermatology excimer lasers are available different modes or systems such as hand held, table top, or trolley mounted devices.
February 18, 2022
·
5 min read
Arthroscopy Shaver Systems Market: Rising elderly population across the globe is expected to drive the market
Arthroscopy is a relatively new surgical procedure that involves minimal invasion and offers rapid recovery.
February 18, 2022
·
5 min read
Drug Development
Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
Regeneron Pharmaceuticals, Inc. and Sanofi announced a Phase 3 trial evaluating Dupixent® in patients with chronic spontaneous urticaria will stop due to futility, based on a pre-specified interim analysis.
February 18, 2022
·
21 min read
BioArctic continues to build its commercial organization
BioArctic AB continues to build the Nordic commercial organization ahead of a potential launch of the company’s lead drug candidate, lecanemab, in the Nordic region.
February 18, 2022
·
7 min read
Business
iZafe Group Q4 Interim Report, October-December 2021
Net sales for the quarter amounted to SEK 220 (84) thousand. The quarter’s sales consist of revenues attributable to the sale of the digital medication robot Dosell.
February 18, 2022
·
6 min read
Antiprotozoal Drugs Market: The Pipeline for New Antiprotozoal Drugs is Projected to Boost the Growth of the Market
Protozoa are unicellular, non-phototrophic, eukaryotic microorganisms lacking cell walls. This group comprises over 65,000 species.
February 18, 2022
·
6 min read
Santhera Completes Repayment of 2017/22 Convertible Bonds
Santhera Pharmaceuticals announces full redemption of its senior unsecured convertible bonds, effective February 17, 2022.
February 18, 2022
·
3 min read
Drug Development
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
A Phase 3 trial evaluating Dupixent® in patients with chronic spontaneous urticaria, who were refractory to omalizumab, will stop due to futility based on a pre-specified interim analysis.
February 18, 2022
·
15 min read
Previous
8 of 12
Next